Findings

What do systematic reviews say?

5 questions · 5 findings · 3 reviews · Gut

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 20%GRADE not reported 0 · 0%Very low 1 · 20%Low 2 · 40%Moderate 1 · 20%High 0 · 0%

Oral viscous budesonide vs swallowed fluticasone

Withdrawals due to adverse events · active EoE patients

Oral viscous budesonide showed no clear difference in withdrawals due to adverse events at 8 weeks compared with swallowed fluticasone (low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 0.98 [0.42, 2.32]
1 study · 129 participants
Low

Swallowed fluticasone vs prednisone

Withdrawals due to adverse events · active EoE pediatric patients

It is very uncertain whether swallowed fluticasone changes withdrawals due to adverse events at 4 weeks compared with oral prednisone (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 0.5 [0.16, 1.53]
1 study · 80 participants
Very low

5‐ASA vs placebo

Withdrawals due to adverse events · patients with maintenance of medically‐induced remission in Crohn's disease

5‐ASA showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 1.11 [0.88, 1.38]
10 studies · 1833 participants
Low

Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide

Withdrawals due to adverse events · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tofacitinib vs placebo

Withdrawals due to adverse events · Patients with quiescent ulcerative colitis

Tofacitinib probably leads to lower withdrawals due to adverse events (5 mg/10 mg) compared with placebo (moderate certainty).

1 finding from 1 review

Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.5 [0.33, 0.77]
1 study · 592 participants
Moderate